READGENE
Research READGENE (RDG.WA) on Bullrun: market cap PLN 59.42M, P/E 50.4. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerRDG.WA
- ExchangeXNCO
- CountryPoland
- SectorHealthcare
- IndustryBiotechnology
- CurrencyPLN
- Market capPLN 59.42M
- P/E50.4
- Financial periodQ2 2026
- RevenuePLN 4.17M
- Net income-PLN 420.19K
- Free cash flow-PLN 211.53K
- Gross margin93.8%
Valuation Snapshot
latest market cap is PLN 59.42M; P/E is 50.4.
Peer valuation comparison
Latest P/E is 50.4x versus a Healthcare sector median of 24.64x (104.5% above).
Latest P/E is 50.4x versus a Poland median of 12.32x (309.2% above).
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-10-11 | PLN 59.42M | 50.4 | n/a | 0 |
Dividend history
Latest trailing dividend snapshot: annual dividend/share 0 PLN.
About READGENE
Read-Gene S.A. engages in the detection, prevention, and treating of various types of cancer in Poland. The company offers chemoprevention that uses natural or synthetic substances to inhibit, reverse, or delay the process of developing cancer. It also provides clinical trials that involves evaluating whether a potential drug, product, or medical technology is effective and safe for the medical, pharmaceutical, chemical, and biotechnological industries. In addition, the company offers genetic tests;
Related stock research
Other Healthcare stocks
Frequently asked questions
What is READGENE's market cap?
READGENE's market capitalization is PLN 59.42M.
What is READGENE's P/E ratio?
READGENE's price-to-earnings (P/E) ratio is 50.4.
What does READGENE do?
Read-Gene S.A. engages in the detection, prevention, and treating of various types of cancer in Poland. The company offers chemoprevention that uses natural or synthetic substances to inhibit, reverse, or delay the process of developing cancer. It also provides clinical trials that involves evaluating whether a potential drug, product, or medical technology is effective and safe for the medical, pharmaceutical, chemical, and biotechnological industries.